The US and Rwandan researchers say they have developed a low-cost smartphone accessory capable of detecting HIV and syphilis from a finger prick of blood in just 15 minutes, Xinhua news agency reported.
This is the first device that replicates all the functions of a
lab-based blood test and works by detecting markers of infectious
diseases: HIV antibody, treponemal-specific antibody for syphilis and
non-treponemal antibody for active syphilis infection.
The manufacturing cost of the device is only US$34, much lower than the
US$18,000 that current gold standard of diagnostics, known as the
enzyme-linked immunosorbent assay (ELISA), needs.
The accessory was recently piloted by health care workers in Rwanda who
used it to test blood finger-pricked from 96 patients, many of whom were
women at risk for mother-to-child transmission of sexually transmitted
The researchers said the device delivered test results displayed on the
phone screen within 15 minutes and performed almost as well as the ELISA
Nearly all patients preferred it to lab-based tests, which could take up to two or more hours.
"Our work shows that a full laboratory-quality immunoassay can be run on
a smartphone accessory," said lead author Samuel Sia, associate
professor of biomedical engineering at Columbia University.
"This kind of capability can transform how health care services are delivered around the world," Sia said.
The device, or dongle, can easily connect to a smartphone or computer.
It is small and light enough to fit into one hand and draws all the
power it needs to run by plugging into a smartphone's audio jack.
Researchers believe that this lab-on-a-chip device could help scale up
early detection of HIV and syphilis especially in mobile or field
"Our dongle presents new capabilities for a broad range of users from health care providers to consumers," Sia said.
"By increasing detection of syphilis infections, we might be able to
reduce deaths by tenfold. We might be able to scale up HIV testing at
the community level with immediate antiretroviral therapy that could
nearly stop HIV transmissions and approach elimination of this disease,"
The work, also comprising researchers from Rwanda Biomedical Centre, was
published in the US journal Science Translational Medicine.